Noetik, a biotech company, is leveraging AI, specifically transformer models like TARIO-2, to address the high failure rate in cancer clinical trials. Their approach focuses on better matching patients with specific tumor types to existing treatments, rather than discovering new drugs. This strategy has led to a significant $50 million deal with GSK, marking a shift towards licensing AI platforms rather than developing drugs directly. AI
排序理由 Biotech company secures a $50M deal with a major pharmaceutical firm for its AI platform.
- Daniel Bear
- GSK
- H&E assay
- Latent Space
- Opdivo
- Keytruda
- Ron Alfa
- TARIO-2
- Transformer
- Trastuzumab
- Noetik
AI 生成摘要 · Google Gemini · 来自 2 个来源。 我们如何撰写摘要 →
